Inmune Bio Inc. (INMB)
Stock Price:
$7.66 USD
-0.14 (-1.79%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $7.70 +0.04 (0.52%) Oct 30, 7:58 PM
Key Info
| Market Cap |
103.01M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-9.56M |
| Shares Out |
13.45M |
| EPS (ttm) |
-0.89 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$7.66 |
| Previous Close |
$7.80 |
| Change ($) |
-0.14 |
| Change (%) |
-1.79% |
| Day's Open |
7.84 |
| Day's Range |
7.28 - 7.84 |
| Day's Volume |
121,614 |
| 52-Week Range |
2.20 - 24.42 |
More Stats
| Market Cap |
103.01M |
| Enterprise Value |
98.35M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.45M |
| Float |
6.69M |
| EPS (basic) |
-0.89 |
| EPS (diluted) |
-0.89 |
| FCF / Share |
-0.48 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
518,205 |
| Short Ratio |
3.41 |
| Short % of Float |
7.75% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.84 |
| Revenue |
n/a |
| Operating Income |
-9.62M |
| Net Income |
-9.56M |
| Free Cash Flow |
-5.23M |
| Net Cash |
4.66M |
| Net Cash / Share |
0.35 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-23.77% |
| ROE |
-39.42% |
| ROIC |
-1,504.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$21.25*
(177.42% upside)
Low
16.0
Current: $7.66
High
26.0
Target: 21.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -7.76 | -12.44 | -0.98 | -0.23 |
| Net Income | -7.68 | -12.44 | -0.83 | -0.28 |
| Shares Outstanding | 10.27 | 8.68 | 6.56 | 5.00 |
| Earnings Per Share | -0.75 | -1.43 | -0.13 | -0.06 |
| Operating Cash Flow | -5.38 | -2.06 | -0.76 | -0.32 |
| Free Cash Flow | -5.38 | -2.06 | -0.76 | -0.32 |
| Cash & Equivalents | 7.00 | 0.19 | 1.37 | 0.14 |
| Total Debt | 0.17 | - | - | 0.35 |
| Net Cash / Debt | 6.83 | 0.19 | 1.37 | -0.21 |
| Assets | 24.47 | 17.36 | 18.41 | 0.45 |
| Liabilities | 0.86 | 0.82 | 0.31 | 0.60 |
| Book Value | 23.61 | 16.54 | 18.10 | -0.15 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Inmune Bio Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Raymond J. Tesi |
Stock Information
| Ticker Symbol |
INMB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: INMB |
| IPO Date |
February 4, 2019 |
Description
INmune Bio, a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.